New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis.
Autor(es): Miyamoto Katsuichi; Oka Nobuyuki; Kawasaki Teruaki; Miyake Sachiko; Yamamura Takashi; Akiguchi Ichiro
Resumo: We analyzed two new cyclooxygenase-2 (COX-2) inhibitors, celecoxib (SC-58635) and meloxicam, for the treatment of experimental autoimmune neuritis (EAN) in rats. Celecoxib and meloxicam significantly reduced clinical EAN score and histopathological damage of the sciatic nerve. They induced no serious side effects, whereas indomethacin used as a control caused severe intestinal ulceration and dysfunction of liver and kidney. These findings suggest that the new COX-2 inhibitors may be useful as additional therapeutic agents for patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
Imprenta: Muscle & Nerve, v. 25, n. 2, p. 280-282, 2002
Identificador do objeto digital: 10.1002/mus.10019
Descritores: Guillain-Barre Syndrome - Cytopathology ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Epidemiology ; Guillain-Barre Syndrome - Immunology
Data de publicação: 2002
